Fault tolerant SVM strategy for 3-level NPC inverter von Ben Abdelghani, H, Ben Abdelghani, A B

Volltext bestellen

Three level fault tolerant DTC control for induction machine drives von Ben Abdelghani, Hafedh, Ben Abdelghani, Afef B., Slama-Belkhodja, I.

Volltext bestellen

Renal impairment in multiple myeloma : a single center experience von Barbuch, S., Mayara, M., Gorsane, Imen, Bin Abd al-Ghani, K., Goucha, R., Bin Hamidah, F., Hedri, H., Bin Abd Allah, T.

Volltext

Thermal decomposition kinetic of 1,1-di(tert-butylperoxy)cyclohexane in organic solvents von Talouba, I. Ben, Bensahlam, N., Medjkoune, H., Mouhab, N., Balland, L., Abdelghani-Idrissi, M.A.

Volltext

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial von Bennouna, Jaafar, MD, Sastre, Javier, MD, Arnold, Dirk, Prof, Österlund, Pia, MD, Greil, Richard, Prof, Van Cutsem, Eric, Prof, von Moos, Roger, MD, Viéitez, Jose Maria, MD, Bouché, Olivier, Prof, Borg, Christophe, MD, Steffens, Claus-Christoph, MD, Alonso-Orduña, Vicente, MD, Schlichting, Christoph, MD, Reyes-Rivera, Irmarie, MD, Bendahmane, Belguendouz, MD, André, Thierry, Prof, Kubicka, Stefan, Prof

Volltext

507O Impact of lean body mass-based oxaliplatin dosage on neurotoxicity in adjuvant treatment of stage III colorectal cancer: Final results of the phase II randomized multicenter L... von Assenat, E., Ben Abdelghani, M., Gourgou, S., Perrier, H., Akouz, F. Khemissa, Desgrippes, R., Galais, M.P., Janiszewski, C., Rinaldi, Y., Lepage, C., Tetreau, R., Senesse, P.

Volltext

Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study von Phelip, Jean Marc, Desrame, Jérôme, Edeline, Julien, Barbier, Emilie, Terrebonne, Eric, Michel, Pierre, Perrier, Hervé, Dahan, Laetitia, Bourgeois, Vincent, Akouz, Faiza Khemissa, Soularue, Emilie, Ly, Valérie Lebrun, Molin, Yann, Lecomte, Thierry, Ghiringhelli, François, Coriat, Romain, Louafi, Samy, Neuzillet, Cindy, Manfredi, Sylvain, Malka, David

Volltext

496TiP Randomised phase II study evaluating trifluridine/tipiracil (FTD/TPI) plus oxaliplatin ± nivolumab versus FOLFOX ± nivolumab in patients with HER2-negative locally advanced,... von de la Fouchardiere, C., Chabaud, S., Perrier, H., Ammarguellat, H., Jestin, V., Olesinski, J., Toullec, C., Aparicio, T., Ben Abdelghani, M., Bouche, O., Coutzac, C., Dubreuil, O., Evesque, L., Muller, M., Poureau, P-G., Soularue, E., Tougeron, D., Zaanan, A., De Sousa Carvalho, N., Botsen, D.

Volltext

387MO Tumour mutation profiles and circulating tumour cells in metastatic colorectal cancer patients treated with FOLFIRI + cetuximab: A prospective ancillary study of the UNICANCE... von Blons, H., Polivka, V., Francois, E., Ben Abdelghani, M., Phelip, J.M., Lebrun-Ly, V., Mineur, L., Garinet, S., Farace, F.F., Lachaux, N., Gourgou, S., Bouche, O., Boige, V.

Volltext

562P Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II tr... von Boige, V., Bouche, O., Mulot, C., Evesque, L., Ben Abdelghani, M., Phelip, J.M., Mineur, L., Galais, M.P., Villing, A-L., Hautefeuille, V., Fouchardiere, C. de la, Genet, D., Lassoued, S., Carnot, A., Mitry, E., Jacquot, S., Serazin, D., Brument, E., Winter, A., Blons, H.

Volltext

572P Tolerance of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34 – FFCD 1402 - ADAGE randomized phase III trial von Aparicio, T., Etienne, P-L., Bouche, O., Barbier, E., Hiret, S., Ammarguellat, H., Desgrippes, R., Martin, J., Meyer, V. Guerin, Le Brun-Ly, V., Ben Abdelghani, M., Falandry, C., Turpin, J., Rinaldi, Y., Desrame, J., Darrius, R., Villing, A-L., Furtos, C.I., Lepage, C., Mineur, L.

Volltext

47P Does metastatic site influence the outcome in colorectal cancer patients treated with regorafenib? Insights from the phase II randomized study SOREGATT - PRODIGE 68 - UCGI 38 von Smolenschi, C., Tanguy, M-L., Ben Abdelghani, M., Parzy, A., Tougeron, D., Bouche, O., Martin-Babau, J., Bachet, J-B., Taieb, J., Viaud, J., Khemissa Akouz, F., Fares, N., Castanie, H., Etchepare, N., Cacheux, W., Coutzac, C., Botsen, D., Mailleux, M., Ducreux, M.P., Boileve, A.

Volltext

3O PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in... von Ducreux, M.P., Ben Abdelghani, M., Tougeron, D., Bouche, O., Viaud, J., Khemissa Akouz, F., Martin-Babau, J., Bachet, J-B., Coutzac, C., Castanie, H., Taieb, J., Phelip, J.M., Fares, N., Cacheux, W., Etchepare, N., Botsen, D., Mailleux, M., Chevrot, M., Tanguy, M-L., Parzy, A.

Volltext

387P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Final results of the randomized phase II TIME-PRODIGE 28 UNICANCER study von Boige, V., Francois, E., Blons, H., Ben Abdelghani, M., Phelip, J.M., Ly Lebrun, V., Mineur, L., Galais, M.P., Villing, A-L., Hautefeuille, V., Miglianico, L., de la Fouchardiere, C., Genet, D., Levasseur, N., Lachaux, N., Gourgou, S., Castan, F., Bouche, O.

Volltext

1555P Cell-free DNA analysis in patients with metastatic gastroesophageal adenocarcinoma: Preliminary results of the REGIRI - PRODIGE 58 ancillary study von Harlé, A., Merigout, A., Evesque, L., Turpin, A., Tougeron, D., Botsen, D., Muller, M., de la Fouchardiere, C., Dubreuil, O., Zaanan, A., Bouche, O., Ben Abdelghani, M., Watson, S., Dermeche, S., Khemissa Akouz, F., Husson, M., Merlin, J.L., Bach, A-S., Senellart, H., Samalin-Scalzi, E.

Volltext

Incidence and Risk Factors for Post–Renal Transplant Diabetes Mellitus von Hadj Ali, I, Adberrahim, E, Ben Abdelghani, K, Barbouch, S, Mchirgui, N, Khiari, K, Chérif, M, Ounissi, M, Ben Romhane, N, Ben Abdallah, N, Ben Abdallah, T, Ben Maiz, H, Khedher, A

Volltext

429P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: First results of the randomized phase II TIME-PRODIGE28 UNICANCER study... von Boige, V., Francois, E., Ben Abdelghani, M., Phelip, J.M., Lebrun-Ly, V., Mineur, L., Galais, M.P., Villing, A.L., Hautefeuille, V., Miglianico, L., de la Fouchardiere, C., Genet, D., Levasseur, N., Lachaux, N., Blons, H., Castan, F., Gourgou, S., Bouche, O.

Volltext

508TiP PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapie... von Ducreux, M.P., Parzy, A., Ben Abdelghani, M., Martin-Babau, J., Tougeron, D., Botsen, D., Taieb, J., Pannier, D., Khemissa, F., Viaud, J., Villing, A.L., Bouche, O., Peytier, A., Alexandre, H., Garic, F., Tanguy, M-L., Bachet, J-B.

Volltext

Labeled magnetic nanoparticles assembly on polypyrrole film for biosensor applications von Fredj, H. Ben, Helali, S., Esseghaier, C., Vonna, L., Vidal, L., Abdelghani, A.

Volltext

Rapid detection of immunoglobulin G against Mycobacterium tuberculosis antigens by two commercial ELISA kits von BEN SELMA, W, HARIZI, H, MARZOUK, M, BEN KAHLA, I, BEN LAZREG, F, FERJENI, A, HARRABI, I, ABDELGHANI, A, BEN SAID, M, BOUKADIDA, J

Volltext